Hubungan keberhasilan terapi pneumonia nosokomial resisten Pseudomonas aeruginosa dan Acinetobacter baumannii dengan dosis Karbapenem di ICU RS Royal Taruma periode 2012-2017

Article Sidebar

PDF
Published: Oct 29, 2019
DOI: https://doi.org/10.24912/tmj.v2i1.5865
Keywords:
dosis tinggi, karbapenem, Pseudomonas aeruginosa resisten karbapenem, Acinetobacter baumannii resisten karbapenem
Dimensions
Altmetrics
Statistics
Read Counter : 539
Download : 454
Crossmark/ Data Version

Main Article Content

Joseph Deni
Fakultas Kedokteran Universitas Tarumanagara
Frans JV Pangalila
Fakultas Kedokteran Universitas Tarumanagara

Abstract

Perawatan pneumonia nosokomial di ICU pasca infeksi Pseudomonas aeruginosa dan Acinetobacter baumannii yang resisten-karbapenem sangat kompleks dan merupakan masalah kesehatan dunia. Karbapenem dosis tinggi (1,5-2 g IV q8h) diduga mampu meningkatkan penghancuran dan menekan angka kejadian resistensi patogen. Tujuan penelitian ini adalah untuk mengetahui adakah hubungan antara keberhasilan terapi pasien pneumonia nosokomial terinfeksi oleh Pseudomonas aeruginosa dan Acinetobacter baumannii yang resisten karbapenem dengan dosis terapi karbapenem. Penelitian analitik observasional dengan desain potong lintang dan besar sampel sebanyak 22 orang yang memenuhi kriteria seleksi. Data diambil dari rekam medis pasien di ICU RS Royal Taruma selama periode 2012-2017. Analisa statistik dengan menggunakan uji Pearson Chi-square.  Pada penelitian ini, dengan menggunakan karbapenem dosis tinggi (1,5-2 g IV q8h), sebanyak 6 pasien (50%) berhasil sembuh namun 6 pasien (50%) lainnya tidak berhasil sembuh. Dengan karbapenem dosis normal (1g IV q8h), 5 pasien (50%) berhasil sembuh sedangkan 5 pasien lainnya (50%) tidak berhasil sembuh. Analisis statistik tidak menemukan hubungan yang bermakna antara dosis karbapenem dengan keberhasilan terapi pasien pneumonia nosokomial infeksi Pseudomonas aeruginosa dan Acinetobacter baumannii yang resisten karbapenem. (p = 0,66). Dosis karbapenem tidak mempengaruhi keberhasilan terapi pasien pneumonia nosokomial terinfeksi oleh Pseudomonas aeruginosa dan Acinetobacter baumannii yang resisten karbapenem.

Article Details

Issue
Vol. 1 No. 3 (2019): TARUMANAGARA MEDICAL JOURNAL
Section
Artikel Asli
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Penulis yang menerbitkan artikelnya di Tarumanagara Medical Journal (TMJ) setuju dengan ketentuan sebagai berikut:

  1. Penulis mempertahankan hak cipta dan memberikan jurnal hak publikasi pertama dengan bekerja secara bersamaan dilisensikan di bawah Creative Commons Attribution yang memungkinkan orang lain untuk berbagi karya dengan pengakuan atas kepengarangan dari karya asli dan publikasi dalam jurnal ini.
  2. Penulis dapat masuk ke dalam pengaturan kontrak tambahan yang terpisah untuk distribusi non-eksklusif jurnal versi pekerjaan yang dipublikasikan (misalnya, memposting ke repositori institusional atau menerbitkannya dalam buku), dengan pengakuan publikasi awal dalam jurnal ini.
  3. Setiap teks yang dikirim harus disertai dengan "Perjanjian Transfer Hak Cipta" yang dapat diunduh melalui tautan berikut: Unduh
Author Biography

Frans JV Pangalila, Fakultas Kedokteran Universitas Tarumanagara

Bagian Ilmu Penyakit Dalam

References

Friedrich M. Pseudomonas aeruginosa Infections: Practice Essentials, Background, Pathophysiology. 2017 Aug 8 [cited 2017 Sep 22]; Available from: http://emedicine.medscape.com/article/226748-overview

Howard A, O’Donoghue M, Feeney A, Sleator RD. Acinetobacter baumannii. Virulence. 2012 May 1;3(3):243–50.

Brooks GF, Carroll KC, Butel JS, Morse SA, Mietzner TA. Jawetz, Melnick, & Adelberg’s Medical Microbiology. Twenty-Sixth. United States of America: McGRAW-HILL; 2013. 245 p.

Yanagihara K, Kadota J, Aoki N, Matsumoto T, Yoshida M, Yagisawa M, et al. Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in 2010: General view of the pathogens’ antibacterial susceptibility. J Infect Chemother Off J Jpn Soc Chemother. 2015 Jun;21(6):410–20.

Bauman RW. Microbiology with Disease by Body System. Fourth. England: Pearson Education Limited; 2015. 601 p.

WHO | WHO publishes list of bacteria for which new antibiotics are urgently needed [Internet]. WHO. [cited 2017 Nov 22]. Available from: http://www.who.int/ mediacentre/news/releases/2017/bacteria-antibiotics-needed/en/

Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol. 2008 Nov;29(11):996–1011.

Viehman JA, Nguyen M-H, Doi Y. Treatment Options for Carbapenem-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Infections. Drugs. 2014 Aug;74(12):1315–33

Perhimpunan Dokter Paru Indonesia. PNEUMONIA NOSOKOMIAL “PEDOMAN DIAGNOSIS & PENATALAKSANAAN DI INDONESIA” [Internet]. PDPI; 2003 [cited 2017 Sep 7]. Available from: http://pulmonologi.usu.ac. id/images/PDF/Guideline_Pneumonia_Nosokomial_PDPI.pdf.

Brusselaers N, Vogelaers D, Blot S. The rising problem of antimicrobial resistance in the intensive care unit. Ann Intensive Care. 2011 Nov 23;1:47.

Laurence L. Brunton, Lazo JS, Parker KL. Goodman & Gilman’s “The Pharmacological Basic of Theurapetics.” 12th ed. United States of America: McGRAW-HILL; 2011.

Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J, et al. Harrison’s principles of internal medicine. 19th ed. Vol. 2. United States of America: McGRAW-HILL Education; 2015.

Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: Past, Present, and Future ? [Internet]. American Society for Microbiology; [cited 2017 Sep 6]. Available from: http://www.pubmed central.nih.gov/articlerender.fcgi?artid=3195018.

Lenhard JR, Bulitta JB, Connell TD, King-Lyons N, Landersdorfer CB, Cheah S-E, et al. High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii. J Antimicrob Chemother. 2017;72(1):153–65.

Tomas MDM, Cartelle M, Pertega S, Beceiro A, Llinares P, Canle D, et al. Hospital outbreak caused by a carbapenem-resistant strain of Acinetobacter baumannii: patient prognosis and risk-factors for colonisation and infection. Clin Microbiol Infect. 2005 Jul 1;11(7):540–6.

Castle SC. Clinical Relevance of Age-Related Immune Dysfunction. Clin Infect Dis. 2000 Aug 1;31(2):578–85.

Colbert JF, Traystman RJ, Poisson SN, Herson PS, Ginde AA. Sex related differences in the risk of hospital-acquired sepsis and pneumonia post-acute ischemic stroke. J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc. 2016 Oct;25(10):2399–404.

Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ, Barrero-Almodóvar AE, García-Garmendia JL, Bernabeu-Wittell M, et al. Treatment of Multidrug-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia (VAP) with Intravenous Colistin: A Comparison with Imipenem-Susceptible VAP. Clin Infect Dis. 2003 May 1;36(9):1111–8.

Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev. 1993 Oct 1;6(4):428–42.

Rowe T, Araujo KLB, Van Ness PH, Pisani MA, Juthani-Mehta M. Outcomes of Older Adults With Sepsis at Admission to an Intensive Care Unit. Open Forum Infect Dis. 2016 Jan;3(1):ofw010.

Cai B, Echols R, Magee G, Arjona Ferreira JC, Morgan G, Ariyasu M, et al. Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States Predominated by Acinetobacter baumannii and Pseudomonas aeruginosa. Open Forum Infect Dis [Internet]. 2017 Aug 16 [cited 2018 May 23];4(3). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629822/

Rodrigo-Troyano A, Suarez-Cuartin G, Peiró M, Barril S, Castillo D, Sanchez-Reus F, et al. Pseudomonas aeruginosa resistance patterns and clinical outcomes in hospitalized exacerbations of COPD. Respirol Carlton Vic. 2016;21(7):1235–42.

Lodise TP, Sorgel F, Melnick D, Mason B, Kinzig M, Drusano GL. Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia. Antimicrob Agents Chemother. 2011 Apr;55(4):1606–10.

RxKinetics. PK/PD Approach to Antibiotic Therapy Review [Internet]. [cited 2018 May 20]. Available from: http://www.rxkinetics. com/antibiotic_pk_pd.html

Oshima K, Nakamura S, Iwanaga N, Takemoto K, Miyazaki T, Yanagihara K, et al. Efficacy of High-Dose Meropenem (Six Grams per Day) in Treatment of Experimental Murine Pneumonia Induced by Meropenem-Resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother [Internet]. 2016 Dec 27 [cited 2018 May 19];61(1). Available from: https://www. ncbi.nlm.nih.gov/pmc/articles/PMC5192154/

Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis Off Publ Infect Dis Soc Am. 2016 Sep 1;63(5):e61–111.

Landersdorfer CB, Yadav R, Rogers KE, Kim TH, Shin BS, Boyce JD, et al. Combating carbapenem-resistant Acinetobacter baumannii by an optimized imipenem plus tobramycin dosage regimen – prospective validation via hollow fiber infection and mathematical modeling. Antimicrob Agents Chemother. 2018 Jan 16;AAC.02053-17.

Nakamura A, Hosoda M, Kato T, Yamada Y, Itoh M, Kanazawa K, et al. Combined effects of meropenem and aminoglycosides on Pseudomonas aeruginosa in vitro. J Antimicrob Chemother. 2000 Dec;46(6):901–4.

Yadav R, Landersdorfer CB, Nation RL, Boyce JD, Bulitta JB. Novel Approach To Optimize Synergistic Carbapenem-Aminoglycoside Combinations against Carbapenem-Resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2015 Apr 1;59(4):2286–98